S. E. Harper

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis

Loren Laine, S. E. Harper, Thomas Simon et al. · Gastroenterology · 1999 · 476 citations

Anti-inflammatory, Gastrointestinal Pharmacology, Cyclooxygenase 2–Specific +9

Specific inhibition of cyclooxygenase‐2 with MK‐0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

Frank L. Lanza, M F Rack, Thomas Simon et al. · Alimentary Pharmacology & Therapeutics · 1999 · 170 citations

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

Richard H. Hunt, S. E. Harper, Douglas J. Watson et al. · The American Journal of Gastroenterology · 2003 · 161 citations

Complementary studies of the gastrointestinal safety of the cyclo‐oxygenase‐2‐selective inhibitor etoricoxib

Richard H. Hunt, S. E. Harper, P. Callegari et al. · Alimentary Pharmacology & Therapeutics · 2003 · 106 citations · Full text

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

Christopher J. Hawkey, Loren Laine, S. E. Harper et al. · Alimentary Pharmacology & Therapeutics · 2001 · 56 citations · Full text